e-Drug3D

2105

TOVORAFENIB

INN
TOVORAFENIB

cas 1096708-71-2

CLASS

ANTINEOPLASTIC
KINASE INHIBITOR
TREATMENT OF LOW- GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT OR BRAF V600 MUTATION

ROUTE (list)

ORAL

ATC code

PK parameters

Tmax 3 HOUR
VD 103.8 LITER
Cl 1.2 LITER / HOUR
PPB 97.5 PERCENT
t1/2 56 HOUR

Solubility

LOWER THAN 3 MICROGRAMS PER MILLILITER FROM PH 1.2 TO 8

Target

TARGET TYPE II RAF KINASE (MUTANT BRAF V600E, WILD-TYPE BRAF, AND WILD-TYPE CRAF)

PDB
8F7O (BRAF KINASE IN COMPLEX WITH TAK580 (TOVORAFENIB))

Ligand code = QOP (link to the list of PDB complexes)

Download experimental 3D coordinates of QOP with added hydrogens

DrugCentral

Download SDF file

4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]- (ACI)

Formula:
C17H12Cl2F3N7O2S

Calculated chemical properties:

MW 506.31
NB_atoms 32
XLogP 3.98
PSA 116.781
NB_HD 4
NB_HA 9
fsp3 0.18
Lipinski(0=no;1=yes) 0

FDA
NDA 217700 (label) INN (TOVORAFENIB) OJEMDA (DAY ONE BIOPHARMS) APPROVAL= AP YEAR= 2024 NEWMOLECULARENTITY
NDA 218033 (label) INN (TOVORAFENIB) OJEMDA (DAY ONE BIOPHARMS) APPROVAL= AP YEAR= 2024